Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Journal
The lancet. Diabetes & endocrinology
Journal Volume
12
Journal Issue
1
Date Issued
2024-01
Author(s)
Abat, S.
Abd Rahman, R.
Abdul Cader, R.
Abdul Hafidz, M. I.
Abdul Wahab, M. Z.
Abdullah, N. K.
Abdul-Samad, T.
Abe, M.
Abraham, N.
Acheampong, S.
Achiri, P.
Cheng, HT
Acosta, J. A.
Adeleke, A.
Adell, V.
Adewuyi-Dalton, R.
Adnan, N.
Africano, A.
Agharazii, M.
Aguilar, F.
Aguilera, A.
Ahmad, M.
Ahmad, M. K.
Ahmad, N. A.
Ahmad, N. H.
Ahmad, N. I.
Ahmad Miswan, N.
Ahmad Rosdi, H.
Ahmed, I.
Ahmed, S.
Aiello, J.
Aitken, A.
AitSadi, R.
Aker, S.
Akimoto, S.
Akinfolarin, A.
Akram, S.
Alberici, F.
Albert, C.
Aldrich, L.
Alegata, M.
Alexander, L.
Alfaress, S.
Alhadj Ali, M.
Ali, A.
Alicic, R.
Aliu, A.
Almaraz, R.
Almasarwah, R.
Almeida, J.
Aloisi, A.
Al-Rabadi, L.
Alscher, D.
Alvarez, P.
Al-Zeer, B.
Amat, M.
Ambrose, C.
Ammar, H.
An, Y.
Andriaccio, L.
Ansu, K.
Apostolidi, A.
Arai, N.
Araki, H.
Araki, S.
Arbi, A.
Arechiga, O.
Armstrong, S.
Arnold, T.
Aronoff, S.
Arriaga, W.
Arroyo, J.
Arteaga, D.
Asahara, S.
Asai, A.
Asai, N.
Asano, S.
Asawa, M.
Asmee, M. F.
Aucella, F.
Augustin, M.
Avery, A.
Awad, A.
Awang, I. Y.
Awazawa, M.
Axler, A.
Ayub, W.
Azhari, Z.
Baccaro, R.
Badin, C.
Bagwell, B.
Bahlmann-Kroll, E.
Bahtar, A. Z.
Baigent, C.
Bains, D.
Bajaj, H.
Baker, R.
Baldini, E.
Banas, B.
Banerjee, D.
Banno, S.
Abstract
The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population.
SDGs
Type
journal article